- Defence Therapeutics has begun its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule prior to initiating its Phase I trial in breast cancer patients
- Eurofins has been mandated by Defence to complete all final GLP studies required by the FDA and Health Canada on its lead AccuTOX molecule
- Pre-clinical studies conducted by the Defence team on mice revealed the effectiveness of the Accum molecule at inhibiting tumor cell growth both in vitro and in vivo
- Defence Therapeutics is a biotechnology company
- Defence Therapeutics Inc. (DTC) opened trading at C$5.10 per share
Defence Therapeutics (DTC) has begun its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited.
Eurofins Advinus Limited is a leading drug discovery and development contract research organization.
Eurofins has been mandated by Defence to complete all final GLP studies required by the FDA and Health Canada on its lead AccuTOX molecule. The studies will be conducted on both rats (rodents) and dogs (non-rodents) to identify the maximum tolerated dose in addition to evaluating the pharmacokinetic and toxicology profile of the lead compound.
Mr. Plouffe, the CEO of Defence commented on the AccuTOX program.
“We are pleased with our very efficient advancement in the AccuTOX program. Not only did the Accum elicit powerful anti-cancer properties, but in addition we screened a series of variants (>50) to identify the lead AccuTOX molecule capable of efficiently killing more than 9 different tumor cell lines of both murine and human origin (lymphoma, melanoma, breast, colon and non-small cell lung carcinoma). Completing this set of GLP studies represents therefore the final step before approaching the FDA/Health Canada to initiate a Phase I trial in breast cancer patients in 2022.”
The global breast cancer therapeutics market will reach US38.5 billion by the end of 2026.
Pre-clinical studies conducted by the Defence team on mice revealed the effectiveness of the Accum molecule at inhibiting tumour cell growth both in vitro and in vivo. In addition, Accum was shown to elicit additive effects in animals when used in conjunction with immune-checkpoint inhibitors such as CTLA-4 and PD-1, two antibodies currently being used in the oncology clinic to treat cancer patients.
Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$5.10 per share.
